Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.39 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244332 | 0.92 | PIP4K2C (0.48) | PIP4K2CBRAFMAPK14MCHR1PIP4K2A | |
| SCHEMBL1243893 | 0.89 | PIP4K2C (0.51) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL28621552 | 0.87 | PIP4K2C (0.46) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL1244474 | 0.87 | CDK9 (0.46) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL1244513 | 0.86 | PIP4K2C (0.49) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL1244614 | 0.85 | PIP4K2C (0.44) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL1244422 | 0.85 | KDM4E (0.54) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| SCHEMBL16415895 | 0.85 | PIP4K2C (0.46) | PIP4K2CBRAFMAPK14PIP4K2APIP4K2B | |
| SCHEMBL1241068 | 0.85 | PIP4K2C (0.44) | PIP4K2CMCHR1PIP4K2APIP4K2BPIKFYVE | |
| SCHEMBL1243658 | 0.85 | ABL1 (0.49) | PIP4K2CBRAFMAPK14PIP4K2APIP4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | claimed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
| EP-3024457-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIP4K2C 4147/4885BRAF 908/4885MAPK14 4493/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIP4K2C 3538/4885BRAF 862/4885MAPK14 4689/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIP4K2C 4147/4885BRAF 908/4885MAPK14 4493/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | PIP4K2C 52/4885BRAF 43/4885MAPK14 174/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PIP4K2C 4240/4885BRAF 2833/4885MAPK14 4442/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PIP4K2C 3538/4885BRAF 862/4885MAPK14 4689/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIP4K2C 4198/4885BRAF 1740/4885MAPK14 4718/4885 |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIP4K2C 4198/4885BRAF 1740/4885MAPK14 4718/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIP4K2C 4147/4885BRAF 908/4885MAPK14 4493/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | PIP4K2C 4198/4885BRAF 1740/4885MAPK14 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.